Pharmacological Properties of Aceclofenac and Pregabalin
These are two distinct medications with completely different mechanisms of action that are sometimes used together for pain management.
Aceclofenac
Aceclofenac is a phenylacetic acid derivative NSAID with potent anti-inflammatory and analgesic properties through COX-2 inhibition 1. It demonstrates comparable efficacy to diclofenac and indomethacin but with a notably lower gastric ulcerogenic potential—approximately 7-fold less than indomethacin and 2-fold less than diclofenac 2.
Mechanism of Action
- COX-2 selective inhibition reducing prostaglandin synthesis
- Anti-inflammatory activity similar to diclofenac but with improved gastrointestinal safety profile 1
- Effective against both acute and chronic inflammatory conditions 2
Clinical Pharmacology
- Demonstrates superior therapeutic ratio compared to indomethacin, diclofenac, naproxen, and phenylbutazone due to high anti-inflammatory activity combined with lower gastric toxicity 2
- Effective in rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis with efficacy equivalent to or better than comparator NSAIDs 1
Pregabalin
Pregabalin binds with high affinity to the alpha2-delta subunit of voltage-gated calcium channels in the CNS, reducing calcium-dependent release of pro-nociceptive neurotransmitters 3.
Mechanism of Action
- Primary target: Alpha2-delta subunit of voltage-gated calcium channels 3
- Reduces synaptic release of glutamate, norepinephrine, and substance P in the spinal cord 3
- Does NOT act through GABA receptors, sodium channels, opioid receptors, or COX pathways 3
- Does NOT inhibit serotonin, dopamine, or noradrenaline reuptake 3
- May enhance descending noradrenergic and serotonergic pain modulation pathways 3
Pharmacokinetics
- Bioavailability: ≥90%, independent of dose 3
- Peak plasma concentration: 1.5 hours (fasting); 3 hours (with food) 3
- Steady state: Achieved within 24-48 hours 3
- Half-life: Approximately 6 hours 3
- Protein binding: None 3
- Metabolism: <2% metabolized; eliminated unchanged via renal excretion 3
- Linear pharmacokinetics allowing predictable dose-response relationship 4
Dosing (from Guidelines)
Start at 50 mg three times daily or 75 mg twice daily, increase to 300 mg/day after 3-7 days, then by 150 mg/day every 3-7 days as tolerated to maximum 600 mg/day 5. Dosages above 300 mg/day are not consistently more effective and carry higher adverse effect rates 5. Requires dose reduction in renal insufficiency 5.
Adverse Effects
- Dose-dependent dizziness and sedation (mitigated by slow titration) 5
- Additive CNS depression when combined with opioids, benzodiazepines, or alcohol 3
- Schedule V controlled substance in the United States due to dependence potential 5
Drug Interactions
Pregabalin has minimal pharmacokinetic drug interactions due to lack of protein binding, negligible metabolism, and no effect on cytochrome P450 enzymes 3. No interactions with common antiepileptic drugs including carbamazepine, valproic acid, lamotrigine, phenytoin, phenobarbital, or topiramate 3.
Combined Use
When aceclofenac and pregabalin are prescribed together for chronic pain (particularly neuropathic pain with inflammatory components), they provide complementary mechanisms: peripheral anti-inflammatory action (aceclofenac) and central neuropathic pain modulation (pregabalin) 6. However, long-term combined use requires monitoring for pregabalin dependence 7 and potential testicular toxicity in males with prolonged exposure 8.
Important Caveats
- Pregabalin requires 4 weeks for adequate therapeutic trial at maximum tolerated dose 5
- Both medications require dose adjustment in renal impairment
- The combination may be effective for lumbosacral radiculopathy with neuropathic components 6
- Avoid abrupt pregabalin discontinuation—taper gradually to prevent withdrawal symptoms